BACKGROUND AND PURPOSE: Previous clinical studies suggested benefit for poststroke recovery when MLC601 was administered between 2 weeks and 6 months of stroke onset. The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested the hypothesis that MLC601 is superior to placebo in acute, moderately severe ischemic stroke within a 72-hour time window. METHODS: This multicenter, double-blind, placebo-controlled trial randomized 1100 patients with a National Institutes of Health Stroke Scale score 6 to 14, within 72 hours of onset, to trial medications for 3 months. The primary outcome was a shift in the modified Rankin Scale. Secondary outcomes were modified Rankin Scale dichotomy, National Institutes of Health Stroke Scale improvement, difference in National Institutes of Health Stroke Scale total and motor scores, Barthel index, and mini-mental state examination. Planned subgroup analyses were performed according to age, sex, time to first dose, baseline National Institutes of Health Stroke Scale, presence of cortical signs, and antiplatelet use. RESULTS: The modified Rankin Scale shift analysis-adjusted odds ratio was 1.09 (95% confidence interval, 0.86-1.32). Statistical difference was not detected between the treatment groups for any of the secondary outcomes. Subgroup analyses showed no statistical heterogeneity for the primary outcome; however, a trend toward benefit in the subgroup receiving treatment beyond 48 hours from stroke onset was noted. Serious and nonserious adverse events rates were similar between the 2 groups. CONCLUSIONS:MLC601 is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity. Longer treatment duration and follow-up of participants with treatment initiated after 48 hours may be considered in future studies. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00554723.
RCT Entities:
BACKGROUND AND PURPOSE: Previous clinical studies suggested benefit for poststroke recovery when MLC601 was administered between 2 weeks and 6 months of stroke onset. The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested the hypothesis that MLC601 is superior to placebo in acute, moderately severe ischemic stroke within a 72-hour time window. METHODS: This multicenter, double-blind, placebo-controlled trial randomized 1100 patients with a National Institutes of Health Stroke Scale score 6 to 14, within 72 hours of onset, to trial medications for 3 months. The primary outcome was a shift in the modified Rankin Scale. Secondary outcomes were modified Rankin Scale dichotomy, National Institutes of Health Stroke Scale improvement, difference in National Institutes of Health Stroke Scale total and motor scores, Barthel index, and mini-mental state examination. Planned subgroup analyses were performed according to age, sex, time to first dose, baseline National Institutes of Health Stroke Scale, presence of cortical signs, and antiplatelet use. RESULTS: The modified Rankin Scale shift analysis-adjusted odds ratio was 1.09 (95% confidence interval, 0.86-1.32). Statistical difference was not detected between the treatment groups for any of the secondary outcomes. Subgroup analyses showed no statistical heterogeneity for the primary outcome; however, a trend toward benefit in the subgroup receiving treatment beyond 48 hours from stroke onset was noted. Serious and nonserious adverse events rates were similar between the 2 groups. CONCLUSIONS: MLC601 is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity. Longer treatment duration and follow-up of participants with treatment initiated after 48 hours may be considered in future studies. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00554723.
Entities:
Keywords:
NeuroAiD; clinical trial; medicine, Chinese traditional; recovery of function; stroke, acute
Authors: Narayanaswamy Venketasubramanian; Chun Fan Lee; Sherry H Young; San San Tay; Thirugnanam Umapathi; Annabelle Y Lao; Herminigildo H Gan; Alejandro C Baroque Ii; Jose C Navarro; Hui Meng Chang; Joel M Advincula; Sombat Muengtaweepongsa; Bernard P L Chan; Carlos L Chua; Nirmala Wijekoon; H Asita de Silva; John Harold B Hiyadan; Nijasri C Suwanwela; K S Lawrence Wong; Niphon Poungvarin; Gaik Bee Eow; Christopher L H Chen Journal: Cerebrovasc Dis Date: 2016-11-15 Impact factor: 2.762
Authors: Joonki Kim; David Yang-Wei Fann; Raymond Chee Seong Seet; Dong-Gyu Jo; Mark P Mattson; Thiruma V Arumugam Journal: Neuromolecular Med Date: 2016-05-18 Impact factor: 3.843
Authors: Nijasri C Suwanwela; Christopher L H Chen; Chun Fan Lee; Sherry H Young; San San Tay; Thirugnanam Umapathi; Annabelle Y Lao; Herminigildo H Gan; Alejandro C Baroque Ii; Jose C Navarro; Hui Meng Chang; Joel M Advincula; Sombat Muengtaweepongsa; Bernard P L Chan; Carlos L Chua; Nirmala Wijekoon; H Asita de Silva; John Harold B Hiyadan; Ka Sing Lawrence Wong; Niphon Poungvarin; Gaik Bee Eow; Narayanaswamy Venketasubramanian Journal: Cerebrovasc Dis Date: 2018-09-05 Impact factor: 2.762